Who
Dennis M. Fenton
Director
Company insider
Files Form 4 as: Director, First Tracks Biotherapeutics; Director, AnaptysBio; Director, Portola Pharmaceuticals; Director, Sienna Biopharmaceuticals; Director, Pfenex; Director, Xenoport; Director, Kythera Biopharmaceuticals; Director, Hospira.
In numbers
- Trades disclosed
- 222
- Buys
- 3
- Sells
- 8
- Bought
- $51K
- Sold
- $12.6M
- Companies
- 11
- Companies where not an officer
- 10
- First trade
- 28 Feb 2001
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,030 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,507 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,507 at $0.00 | filing |
News
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?AMGN · insidermonkey.com · 21 Oct 2026Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)ANAB · tickerreport.com · 20 Oct 2026Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AMGN · fool.com · 20 Oct 2026AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026AMGN · prnewswire.com · 20 Oct 2026
0 headlines in the last 90 days name Dennis M. Fenton; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.